Teva Pharmaceutical Industries stock names R&D transition lead
Published on 11/19/2026 at 10:50 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSLeadership change and pipeline plans
- Eric Hughes will leave Teva after accepting an external offer and will support the transition for several months.
- David Gardiner becomes R&D transition lead immediately while Teva searches for a permanent successor.
- Teva says its R&D priorities remain unchanged, including its ambition to generate 6-7 billion dollars in innovative-medicines revenue by 2030.
Teva Pharmaceutical Industries announced on November 18 that Eric Hughes, its executive vice president of Global R&D and chief medical officer, will leave the company after accepting an external offer. Hughes will remain for the coming months to support the transition, according to a GlobeNewswire release carried by Financial Times.
Transition plan for R&D
David Gardiner, Teva's head of Innovative Medicines and Clinical Development, will serve as the R&D transition lead with immediate effect. He will report to President and CEO Richard Francis until Teva appoints a permanent successor, while the company begins a search for that successor.
Hughes' departure follows Teva's R&D Day on November 11, when the company presented its pipeline and longer-term growth plans. Francis said the strategy, priorities and expectations remain unchanged, while Teva continues to pursue its ambition of generating 6-7 billion dollars in innovative-medicines revenue by 2030.
Pipeline execution remains central
The leadership change places execution of Teva's innovation strategy under an interim structure. The company said its focus remains on the commitments presented at R&D Day and on maintaining momentum across its innovative pipeline.
Teva Pharmaceutical Industries
- Company: Teva Pharmaceutical Industries Ltd.
- Home exchanges: NYSE and TASE
- Business: Global biopharmaceutical company with generics, biosimilars and innovative medicines
- Leadership event: Eric Hughes departure announced November 18, 2026
In the Israeli market, the TA-35 provides the broader benchmark for local equities.
